aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Neuraly, Inc. is a biotechnology company founded with the mission to develop revolutionary treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company focuses on creating neuro-protective therapies that target new pathways, leveraging innovative scientific research to deliver medicines with the potential to significantly improve patient outcomes. Based in Maryland, Neuraly aims to offer new hope to those affected by progressive neurological disorders through its cutting-edge drug development.
Key figures associated with Neuraly include its founders, whose innovations form the backbone of the company's scientific platform. The company has garnered attention and investment from notable investors in the biotech sector, underscoring its potential impact. Neuraly's achievements include advancing its drug candidates through critical stages of development, positioning itself as a promising player in the fight against debilitating neurodegenerative diseases. Through its pioneering work, Neuraly is making significant strides in transforming the treatment landscape for these conditions.
Operating Status
Active
Main Product(s)
Therapeutics
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Neuraly founded?
Neuraly was founded in 2016.
Where is Neuraly’s headquarters located?
Neuraly’s headquarters is located in London, GB.
When was Neuraly’s last funding round?
Neuraly’s most recent funding round was for $36M (USD) in July 2018.
How many employees does Neuraly have?
Neuraly has 125 employees as of Feb 5, 2024.
How much has Neuraly raised to-date?
As of July 05, 2023, Neuraly has raised a total of $36M (USD) since Jul 18, 2018.
Add Comparison
Total Raised to Date
$36M
USD
Last Update Jul 18, 2018
Last Deal Details
$36M
USD
Jul 18, 2018
Series A
Total Employees Over Time
125
As of Feb 2024
Neuraly Address
London,
Greater London
WC1X 0ND
United Kingdom
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts